Search

Search Constraints

You searched for: Author/Creator Florescu, Marie

Search Results

1. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219. (July 2019)

2. HOUT-14. PROGNOSTIC IMPACT OF FIRST PSEUDOPROGRESSION ON MRI IN GLIOBLASTOMA, AN 11 YEARS EXPERIENCE FROM A CANADIAN UNIVERSITY CENTER. (11th November 2019)

3. HOUT-28. FIRST-LINE TEMOZOLOMIDE VS PCV FOR LOW GRADE GLIOMAS: A 11 YEARS REAL-WORLD DATA FROM CHUM, UNIVERSITY CENTER. (11th November 2019)

4. HOUT-23. ADULT MEDULLOBLASTOMA TREATMENT IMPACT SINCE 2006: A CANADIAN UNIVERSITY CENTER EXPERIENCE. (11th November 2019)

6. 50: Prospective Neurocognitive Functions of Patients Treated with Concurrent Nivolumab and Stereotactic Brain Radiosurgery for NSCLC and RCC Brain Metastases. (October 2021)

7. Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC). (March 2022)

8. BIOS-02. CLINICAL OUTCOMES OF OVER 600 PATIENTS WITH GLIOBLASTOMA TREATED AT A CANADIAN TERTIARY CENTER IN THE PAST 15 YEARS: A COMPARATIVE ANALYSIS WITH THE PIVOTAL STUPP TRIAL. (14th November 2022)

9. Tepotinib Efficacy in a Patient with Non‐Small Cell Lung Cancer with Brain Metastasis Harboring an HLA‐DRB1‐MET Gene Fusion. (8th September 2020)

10. QOL-25. IMPACTS OF IMPLEMENTING A PROSPECTIVE TREATMENT AND SURVEILLANCE PROTOCOL FOR THE MANAGEMENT OF NF2-ASSOCIATED VESTIBULAR SCHWANNOMAS ON TUMOR GROWTH, HEARING OUTCOMES, AND QUALITY OF LIFE. (14th November 2022)